Copper peptides: what the evidence actually shows

Copper peptides are one of the most-studied cosmetic ingredients in dermatology — and one of the most over-claimed. Here is what the primary literature supports, graded honestly.

A molecule your own blood makes

In 1973 Loren Pickart isolated a copper-binding tripeptide — glycyl-L-histidyl-L-lysine (GHK) — from human plasma. In 1980 his group showed in Nature that it works by facilitating copper uptake into cells. Plasma levels fall from ~200 ng/mL at age 20 to ~80 ng/mL by 60.

That decline is real. What it does not prove is that a topical reverses it.

The delivery problem nobody sells you

GHK-Cu is small (340 Da) but its copper coordination makes it highly polar — and polar molecules don't cross the skin's lipid barrier easily. A standard cream delivers very little to the dermal cells that matter. The best human results used penetration-enhanced carriers, not ordinary creams.

The honest verdict

A legitimate, well-tolerated cosmetic ingredient with a genuinely deep mechanistic story — and a lot of marketing that borrows lab-dish findings the human trials never confirmed. Buy a well-formulated, fresh one for gradual improvement in the look of skin; ignore the "repairs and reverses" claims.

The full mechanism map, the human trials one by one, pH-stability notes and a buyer's checklist are in the Library review. The graded citations sit on the Skin & Hair bank.